Q-omics provides the consensus-scored KLHDC1 profile across patient tissues and cancer cell-line models. KLHDC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KLHDC1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, KLHDC1 RNA expression shows 23,207 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight SKCM, THCA, and BRCA as cancer lineages where KLHDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHDC1 survival associations across molecular data types. KLHDC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHDC1 RNA expression–survival associations across cancer types. High KLHDC1 expression shows favorable associations in SKCM, PAAD, MESO, BRCA, LGG and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KLHDC1 RNA expression.
This table summarizes KLHDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KLHDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHDC1 shows lower tumor expression in THCA, KIRC, BLCA, LUSC, LUAD and COAD. The THCA box plot shows higher KLHDC1 RNA expression in normal versus tumor tissue (log2 FC = −1.114, t-test p < 0.001).
This table shows molecular features associated with KLHDC1 in patient tissues and cancer cell lines. In patient samples, KLHDC1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
